Patents Assigned to Biologics, Inc.
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 10660936
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 26, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
  • Cell engaging binding molecules
    Patent number: 10654944
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 19, 2020
    Assignee: Y-BIOLOGICS INC.
    Inventors: Seil Jang, Bum-Chan Park, Young Woo Park
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 10653748
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: May 19, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
  • Composition and method for reducing zoonotic infectious diseases
    Patent number: 10653630
    Abstract: The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioacitve agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 19, 2020
    Assignee: US Biologic, Inc.
    Inventors: Douglas Steven Zatechka, Mason Kauffman, Chris Przybyszewski
  • Self-assembling tripeptides
    Patent number: 10646538
    Abstract: The present invention relates to a method of predicting the propensity of tripeptides to from aggregates in solution. The present invention also provides tripeptides which are able to form aggregates in solution, as well as uses thereof. The present invention also provides nanostructures formed by self-aggregation of tripeptides of the present invention. The present invention also provides pH responsive aggregates as well as methods of screening for the ability of a tripeptide to form a pH dependent aggregate or gel.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: May 12, 2020
    Assignee: ENDO Biologics, Inc.
    Inventors: Rein Ulijn, Tell Tuttle, Pim Frederix, Gary Scott, Yousef Abul-Haija
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 10646545
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 12, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Liquid protein formulations containing cimetidine
    Patent number: 10646571
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 12, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Cell engaging binding molecules
    Patent number: 10640576
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 5, 2020
    Assignee: Y-BIOLOGICS INC.
    Inventors: Seil Jang, Bum-Chan Park, Young Woo Park
  • Cell engaging binding molecules
    Patent number: 10633458
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: April 28, 2020
    Assignee: Y-BIOLOGICS INC.
    Inventors: Seil Jang, Bum-Chan Park, Young Woo Park
  • Beta-lactamases with improved properties for therapy
    Patent number: 10584326
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: March 10, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Allogeneic cellular immunotherapy for opportunistic infection
    Patent number: 10548956
    Abstract: A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: February 4, 2020
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
    Patent number: 10548955
    Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 4, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Compositions and their use for pest control and to induce plant hormone and gene regulation for improved plant production and defense
    Patent number: 10542686
    Abstract: The subject invention provides compositions and methods of using the same for improving plants' defense by employing naturally-derived chemicals. In a specific embodiment, the composition is from Parthenium argentatum Gray, also known as the guayule plant. Preferred compositions can up-or downregulate growth genes responsible for the targeted plants' defense mechanisms in order to create physical and/or chemical barriers, and produce detouring exudates, antagonistic compounds, or fumigating compounds that prevent and treat damages from pests in agronomic or non-agronomic plants.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: January 28, 2020
    Assignee: BEEM BIOLOGICS INC.
    Inventors: Lance William Beem, Stephen Michael Butler, George Benjamin Cloud
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 10543253
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: January 28, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Colon and pancreas cancer peptidomimetics
    Patent number: 10533040
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: January 14, 2020
    Assignee: PRECISION BIOLOGICS, INC.
    Inventor: Xue-Ping Wang
  • Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
    Patent number: 10525102
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: January 7, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Humanized pertussis antibodies and used thereof
    Patent number: 10526400
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 7, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Methods for printing organs and organoids
    Patent number: 10513691
    Abstract: Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: December 24, 2019
    Assignee: PRELLIS BIOLOGICS, INC.
    Inventors: Melanie P. Matheu, Kathryn J. Parkinson, Emma R. Moulton
  • LOX and LOXL2 inhibitors and uses thereof
    Patent number: 10494443
    Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 3, 2019
    Assignee: GILEAD BIOLOGICS, INC.
    Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
  • Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
    Patent number: RE47972
    Abstract: The invention relates to Inter-alpha inhibitor proteins (I?Ip). The invention further relates to processes for purification of I?Ip compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 5, 2020
    Assignee: ProThera Biologics, Inc.
    Inventors: Yow-Pin Lim, Djuro Josic, Douglas C. Hixson